Junshi Biotech (688180.SH): New indications for Tuoyi® and inclusion of Junshida® in the national health insurance catalogue

Zhitong Finance App News, Junshi Biotech (688180.SH) issued an announcement. The company's product treprilizumab injection (product name: Tuoyi®, product code: JS001) has 2 new indications, angerizumab injection (trade name: Junstida®, product code: JS002) successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)” (hereinafter referred to as the “National Medical Insurance Catalogue”) category B. The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2026.

As of the disclosure date of this announcement, the company's 4 commercial products Tuoyi®, adalimizumab injection (trade name: Junmaikang®, product code: UBP1211), remidavir deuterium hydrobromide tablets (trade name: Mindevil®, product code: VV116/JT001), and Junstar® have all been included in the national medical insurance catalogue. Tuoyi® has all 12 indications approved for marketing in mainland China. It is the only anti-PD-1 monoclonal antibody drug used to treat kidney cancer, triple-negative breast cancer, and melanoma in the catalogue; Junshida® was included for the first time, and is the only domestically produced PCSK9 target drug for people who are intolerant to statins in the new catalogue.